Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): Preliminary results of a phase II study

Lung Cancer

Volumn 72, Issue 3, 2011, Pages 327-332

  Xu, Yaping ^a   Ma, Shenglin ^a   Ji, Yongling ^a   Sun, Xiaojiang ^a   Jiang, Hao ^a   Chen, Jianxiang ^a   Du, Xianghui ^a   Zheng, Yuanda ^a   Qiu, Guoqin ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

Concomitant chemotherapy; Locally advanced; Non small cell lung cancer; Pemetrexed; Radiotherapy

Indexed keywords

CARBOPLATIN; CYANOCOBALAMIN; FOLIC ACID DERIVATIVE; PEMETREXED;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION PNEUMONIA; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; SURVIVAL ANALYSIS;

EID: 79955477384     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.09.012     Document Type: Article

References (36)

1. Lee C.B., Stinchcombe T.E., Rosenman J.G., Socinski M.A. Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: evolving role of dose-escalated conformal (3-dimensional) radiation therapy. Clin Lung Cancer 2006, 8:195-202.
2. Dillman R.O., Seagren S.L., Propert K.J., Guerra J., Eaton W.L., Perry M.C., et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990, 323:940-945.
3. Le Chevalier T., Arriagada R., Quoix E., Ruffie P., Martin M., Tarayre M., et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991, 83:417-423.
4. Sause W.T., Scott C., Taylor S., Johnson D., Livingston R., Komaki R., et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995, 87:198-205.
5. Schaake-Koning C., Vanden Bogaert W., Dalesio O., Festen J., Hoogenhout J., van Houtte P., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992, 326:524-530.
6. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S., et al. Phase III study of concurrent versus sequential thoracic radiotherapy incombination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999, 17:2692-2699.
7. Curran W.J., Scott C.B., Langer C.J., Komaki R., Lee J.S., Hauser S., et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003, 22:2499.
8. Zatloukal P., Petruzelka L., Zemanova M., Havel L., Janku F., Judas L., et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004, 46:87-98.
9. Fournel P., Robinet G., Thomas P., Souquet P.J., Lena H., Vergnenegre A., et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienned' Oncologie Thoracique-Groupe Francaisde Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 2005, 23:5910-5917.
10. Dillman R.O., Herndon J., Seagren S.L., Eaton W.L., Green M.R. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996, 88:1210-1215.
11. Arriagada R., Chevalier T., Quoix E., Ruffie P., de Cremoux H., Douillard J.Y., et al. ASTRO plenary: effect of chemotherapy on locally advanced non small cell lung carcinoma: a randomized study of 353 patients. Int J Radiat Oncol Biol Phys 1991, 20:1183-1190.
12. Shih C., Chen V.J., Gossett L.S., Gates S.B., Mackellar W.C., Habeck L.L., et al. LY231514, a pyrrolo [2,3-d] pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997, 57:1116-1123.
13. Bischof M., Weber K.J., Blatter J., Wannemacher M., Latz D. Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro. Int J Radiat Oncol Biol Phys 2002, 52:1381-1388.
14. Seiwert T.Y., Connell P.P., Mauer A.M., Hoffman P.C., George C.M., Szeto L., et al. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res 2007, 13:515-522.
15. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
16. Kelly K., Crowley J., Bunn P.A., Livingston R.B., Zangmeister J., Taylor S.A., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001, 19:3210-3218.
17. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
18. Common toxicity criteria: National Institute of Health, Cancer Therapy Evaluation Program 1993, Division of Cancer Treatment, Bethesda.
19. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
20. Govindan R., Bogart J., Wang X., Hodgson L., Kratzke R., Vokes E.E. Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407. J Clin Oncol 2009, 27:15s. [suppl; abstr 7505].
21. Pfister D.G., Johnson D.H., Azzoli G.C., Sause W., Smith T.J., Baker S., et al. American Society of Clinical Oncology Treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22:330-353.
22. Hirsch F.R., Spreafico A., Novello S., Wood M.D., Simms L., Papotti M. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 2008, 3:1468-1481.
23. Scagliotti G.V., Parikh P., Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-mall-cell lung cancer. J Clin Oncol 2008, 26:3485-3486.
24. Ciuleanu T.E., Brodowicz T., Belani C.P., Kim J., Krzakowski M., Laack E., et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: a phase III study. J Clin Oncol 2008, 26(Suppl.):8011a.
25. Peterson P., Park K., Fossella F., Gatzemeier U., John W., Scagliotti G. Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). EJC Suppl 2007, 5:363-364.
26. Chang M.H., Ahn J.S., Lee J., Kim K.H., Park Y.H., Han J., et al. The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer. Lung Cancer 2010, 69:323-329.
27. Sarries C., Haura E.B., Roig B., Taron M., Abad A., Scagliotti G., et al. Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer. Pharmacogenomics 2002, 3:763-780.
28. Sigmond J., Backus H.H., Wouters D., Temmink O.H., Jansen G., Peters G.J. Induction of resistance to the multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 2003, 66:431-438.
29. Ceppi P., Volante M., Saviozzi S., Rapa I., Novelllo S., Cambieri A., et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006, 107:1589-1596.
30. Eismann U., Oberschmidt O., Ehnert M., Fleeth J., Ludtke F., Struck S., et al. Thymidylate synthase gene expression in solid tumors predicts for response to pemetrexed in vitro. J Clin Oncol 2006, 24(18S):13058.
31. Ceppi P., Volante M., Ferrero A., Righi L., Rapa I., Rosas R., et al. Thymidylate synthase expression in gastropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 2008, 14:1059-1064.
32. Dai H., Chen Y., Elmquist W.F. Distribution of the novel antifolate pemetrexed to the brain. J Pharmacol Exp Ther 2005, 315:222-229.
33. Omlin A., D'Addario G., Gillessen S., Cerny T., von Hessling A., Fruh M. Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung. Lung Cancer 2009, 65:383-384.
34. Bearz A., Garassino I., Tiseo M., Caffo O., Soto-Parra H., Boccalon M., et al. Activity of pemetrexed on brain metastases from non-small cell lung cancer. Lung Cancer 2010, 68:264-268.
35. Dogan M., Yalcin B., Utkan G., Urun Y., Ozal G. Activity of pemetrexed on brain metastases from non-small cell lung cancer: what is the mechanism?. Lung Cancer 2009, 66:399.
36. Vokes E.E., Senan S., Treat J.A., Iscoe N.A. PROCLAIM: a phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. Clin Lung Cancer 2009, 10:193-198.